OncoMatch/Clinical Trials/NCT06809530
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Is NCT06809530 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including QL1706 (bispecific antibody targeting PD-1 and CLTA-4) and Pemetrexed (Alimta) for leptomeningeal metastasis.
Treatment: QL1706 (bispecific antibody targeting PD-1 and CLTA-4) · Pemetrexed (Alimta) — This phase I/II study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal dual checkpoint inhibitor (targeting PD-1 and CTLA-4 with QL1706) in combination with pemetrexed in patients with leptomeningeal metastasis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Cerebrospinal fluid cytopathology is positive
Demographics
Prior therapy
Cannot have received: anti-PD-1 therapy
Exception: previous anti-PD1 therapy-induced pneumonitis, or ongoing >Grade 2 adverse events of such therapy
previous anti-PD1 therapy-induced pneumonitis, or have ongoing >Grade 2 adverse events of such therapy
Lab requirements
Blood counts
wbc≥4000/mm3, plt≥100000/mm3
Kidney function
normal kidney function
Liver function
normal liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06809530 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 21 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify